Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
Deputy AG
Venezuela
Climate change
Meth bust
Michael Cohen
Vladimir Putin
Moon lander
Champions League
SeaWorld rescue
Montana
Allison Janney
Health News
Feb. 22, 2018 / 9:46 AM

Analysis of trial data confirms anti-depressants are effective, researchers say

"This meta-analysis finally puts to bed the controversy on anti-depressants, clearly showing that these drugs do work in lifting mood and helping most people with depression," said Carmine Pariante, a researcher at the Royal College of Psychiatrists.

By
Allen Cone
Twenty-one common antidepressants, including fluoxetine, were all more effective at reducing symptoms of acute depression than a placebo, according to a study of 522 drug trials. Fluoxetine, which includes the brand name Prozac, was among the least effective. Photo by Lanfear's Bane/Wikimedia Commons

Feb. 22 (UPI) -- Antidepressants are more successful at reducing depression symptoms among adults than a placebo, according to an analysis of more than 500 drug trials.

The study found 21 common antidepressants were all more effective at reducing symptoms of acute depression than dummy pills, according to a report published Wednesday in The Lancet, which researchers say confirms the efficacy of the drugs for treatment.

"This meta-analysis finally puts to bed the controversy on anti-depressants, clearly showing that these drugs do work in lifting mood and helping most people with depression," Professor Carmine Pariante, of the Royal College of Psychiatrists, told the BBC.

Researchers reviewed data from 522 clinical trials involving 116,477 adults who received short-term treatment of acute depression over eight weeks between 1979 and 2016. Seventy-eight percent of them were funded by pharmaceutical companies. Among the trials, 9 percent were rated as having high risk of bias, 78 percent as having moderate risk of bias and 18 percent as having low risk of bias.

RELATED Depression linked to reduced levels of amino acid: study

"Our study brings together the best available evidence to inform and guide doctors and patients in their treatment decisions," Dr. Andrea Cipriani, of Oxford University's Department of Psychiatry, said in a release. "Our findings are relevant for adults experiencing a first or second episode of depression -- the typical population seen in general practice."

The drugs ranged in effectiveness from one-third more effective than a placebo to more than twice as effective.

Aside from analyzing the trials, the authors then contacted pharmaceutical companies, original study authors and regulatory agencies for additional information.

RELATED Women in U.S. twice as likely as men to have depression

In the trials, 87,052 participants were randomly assigned to receive a drug and 29,425 to receive placebo. Most of the patients had moderate to severe depression. Trials with patients who also had bipolar depression, symptoms of psychosis or treatment resistant depression were excluded.

With one exception, clomipramine, all of the drugs tested in the trials were found to be more effective than a placebo.

The most effective drugs were agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine and vortioxetine. The least effective were fluoxetine, fluvoxamine, reboxetin and trazodone.

RELATED Study: No evidence at-home cranial stimulation is effective for depression

Researchers also examined tolerability with the best agomelatine, citalopram, escitalopram, fluoxetine, sertraline and vortioxetine. Least tolerable were amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone and venlafaxine.

'"Antidepressants can be an effective tool to treat major depression, but this does not necessarily mean that antidepressants should always be the first line of treatment," Cipriani said. "Medication should always be considered alongside other options, such as psychological therapies, where these are available. Patients should be aware of the potential benefits from antidepressants and always speak to the doctors about the most suitable treatment for them individually."

Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Google health-related searches double a week before ER visit, study says
Morning exercise may lower blood pressure for older, obese people
Study: High-carb, low-protein diets may extend lifespan
Common yeast infection drug linked to miscarriage, birth defects
Food allergy linked to certain form of eczema, study says

Photo Gallery

 
Beijing celebrates annual Lantern Festival

Latest News

At least 70 dead in Bangladesh apartment fire
Prosecutors: Coast Guard officer plotted mass killing
Champions League: Atletico Madrid tops Juventus, Manchester City wins
Detroit Tigers to sign two-time All-Star Josh Harrison
Philadelphia 76ers' Joel Embiid to miss at least one week with knee soreness
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy